Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill could stop the maddening itch of prurigo nodularis

NCT ID NCT07236099

Symptom relief Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 15, 2026 · Updated 4 times

Summary

This study tests an experimental drug called ICP-332 for people with prurigo nodularis, a skin condition causing many intensely itchy bumps. About 135 adults will receive either the drug or a placebo to see if it reduces itching and clears the bumps over 16 weeks. The goal is to find a safe, effective dose to ease this chronic itch.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 135 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Oct 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria : 1. Voluntarily sign informed consent forms before any investigational procedure(s) are performed. 2. Male or female aged between 18 and 75 years at the time of signing the informed consent. 3. Clinical diagnosis of PN by a dermatologist for at least 3 months before the Screening visit. 4. At least 20 pruriginous lesions on the entire body with a bilateral distribution (on both legs, and/or both arms and/or trunk) at both screening and the baseline (Day 1) visits. 5. PP NRS score ≥ 7 at both screening and the baseline (Day 1) visits. 6. IGA-CPG-S score ≥ 3 at both the screening and the baseline (Day 1) visits. 7. History of inadequate response to topical corticosteroid of medium or higher potency or for whom topical treatments are otherwise medically inadvisable (e.g., because of important side effects or safety risks). Willingness to avoid pregnancy or fathering children Exclusion Criteria: 1. Patients with a documented AD severity moderate to severe presence of skin morbidities other than PN and mild AD that may interfere with the assessment of the study outcomes. PN secondary to medications . 2. Any uncontrolled or serious disease, or any medical, psychological, or surgical condition including relevant laboratory abnormalities at screening that may either interfere with the interpretation of the clinical trial results and/or, in the investigator's judgment, would adversely affect the patient's participation in the study. Active chronic or acute infection participant not suitable for participation, whatever the reason, as judged by the Investigator, including medical or clinical conditions, or participants potentially at risk of noncompliance to study procedures.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prurigo nodularis (PN) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

prurigo nodularis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prurigo nodularis (PN)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    43 sites in 5 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • AKK MEDlCAL Spółka z ograniczoną Odpowiedzialnością, Centrum Medyczne Tu się Leczy

    RECRUITING

    Gdansk, 80-280, Poland

  • Affiliated Hangzhou First People's Hospital,School of Medicine ,Westlake University

    RECRUITING

    Hangzhou, Zhejiang, 250022, China

  • Amicare Centrum Medyczne

    RECRUITING

    Lodz, 91-495, Poland

  • Apex Clinical Research Center

    RECRUITING

    Mayfield Heights, Ohio, 44124, United States

  • Cahaba Dermatology and Skin Health Center

    RECRUITING

    Birmingham, Alabama, 35244, United States

  • Center for Dermatology Clinical Research, Inc.

    RECRUITING

    Fremont, California, 94538, United States

  • Centrum Badawcze Panaceum

    RECRUITING

    Malbork, 82-200, Poland

  • Chengdu Second People's Hospital

    RECRUITING

    Chengdu, Sichuan, 610021, China

  • Chu de Brest - Hopital Morvan

    RECRUITING

    Brest, 29690, France

  • Cordova Research Institute

    RECRUITING

    Sweetwater, Florida, 33182, United States

  • Dawes Fretzin Clinical Research Group LLC

    RECRUITING

    Indianapolis, Indiana, 46250, United States

  • Dermatologischen Gemeinschaftspraxis Dres. Quist

    RECRUITING

    Mainz, 55128, Germany

  • Dermatology Hospital of Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 510091, China

  • Driven Research, LLC

    RECRUITING

    Miami, Florida, 33126, United States

  • International Clinical Research - Tennessee LLC

    RECRUITING

    Murfreesboro, Tennessee, 37130, United States

  • Jingzhou Central Hospital

    RECRUITING

    Jingzhou, Hubei, 434020, China

  • Klinika Ambroziak Dermatologia

    RECRUITING

    Warsaw, 25-553, Poland

  • Medical Dermatology Specialists

    RECRUITING

    Phoenix, Arizona, 85006, United States

  • Minnesota Clinical Study Center

    RECRUITING

    New Brighton, Minnesota, 55112, United States

  • Oakland Hills Dermatology

    RECRUITING

    Auburn Hills, Michigan, 48326, United States

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

  • Revival Research Institute, LLC

    RECRUITING

    Troy, Michigan, 48084, United States

  • Rosenpark Research

    RECRUITING

    Darmstadt, 64283, Germany

  • Shandong Provincial Dermatology Hospital

    RECRUITING

    Jinan, Shandong, 250022, China

  • Shenyang Seventh People's Hospital

    RECRUITING

    Shenyang, Liaoning, 110003, China

  • Sichuan Provincial People's Hospital

    RECRUITING

    Chengdu, Sichuan, 610072, China

  • Skin Specialists, PC

    RECRUITING

    Omaha, Nebraska, 68144, United States

  • Specderm Poznanska

    RECRUITING

    Bialystok, 15-375, Poland

  • StracSkin, PLLC

    RECRUITING

    Portsmouth, New Hampshire, 03801, United States

  • The Derm Institute of West Michigan

    RECRUITING

    Caledonia, Michigan, 49316, United States

  • The First Affiliated Hospital of Chongqing Medical University

    RECRUITING

    Chongqing, Chongqing Municipality, 400016, China

  • The First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, Fujian, 350005, China

  • The First Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Hebei, 050000, China

  • The Second Affiliated Hospital of Wannan Medical University

    RECRUITING

    Wuhu, Anhui, 241000, China

  • The first hospital of Jilin University

    RECRUITING

    Changchun, Jilin, 130021, China

  • Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, 300131, China

  • Twoja Przychodnia

    RECRUITING

    Nowa Sól, 67-100, Poland

  • Twoja Przychodnia Centrum Medyczne

    RECRUITING

    Poznan, 60-324, Poland

  • Uni Berlin Chartie Derma

    RECRUITING

    Berlin, 12203, Germany

  • Uni Leipzig Derma

    RECRUITING

    Leipzig, 04103, Germany

  • Uniwersytecki Szpital Kliniczny

    RECRUITING

    Rzeszów, 35-055, Poland

  • Xiangya Hospital of Central South University

    RECRUITING

    Changsha, Hunan, 410008, China

  • Zdybski Ned SP.Z.O.O

    RECRUITING

    Kielce, 25-553, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.